Quality of Evidence:
Coadministration has not been studied. Piperacillin is eliminated renally via glomerular filtration and active renal secretion by OAT1/3. Piperacillin can compete with tenofovir (derived from tenofovir-DF) for active tubular secretion resulting in higher tenofovir concentrations and thereby a related increased risk of nephrotoxicity. In addition, tenofovir-DF should be avoided with concurrent use of drugs that can increase nephrotoxicity such as piperacillin/tazobactam combined with vancomycin. If concomitant use is unavoidable, renal function should be monitored weekly.
View all available interactions with
Tenofovir-DF (TDF) by clicking